Background :

The growing global epidemic of HIV/AIDS has made it the fourth leading cause of the wordwide
death. HIV/AIDS represents a growing concern to healthcare workers and physians in the world with a
current estimed prevalence of close to 40 million worldwide with HIV/AIDS.1 Treatment options for
HIV infection have greatly expanded in the past few years, include the combination of regiments that
significantly prolong survival of HIV-affected individuals.2 One of the regiments, called highly active
antiretroviral therapy (HAART). This therapy has greatly increased the potential for drug interactions
and risks for serious adverse effects. HIV population may be particularly prone to develope long QT
syndrome and ventricular tachycardia.3